Bai Yang, Liu Yanjing, Han Shichao, Song Wenqi
Business School, Shandong University of Technology, Zibo, China.
Department of Ophthalmology, Zibo Central Hospital, Zibo, China.
Heliyon. 2024 Jul 4;10(14):e33963. doi: 10.1016/j.heliyon.2024.e33963. eCollection 2024 Jul 30.
This study explores the impact of government subsidies on the production dynamics within the medical product supply chain, particularly focusing on the remanufacturing of medical goods. Amidst the backdrop of the COVID-19 pandemic, which has underscored the critical shortages in medical supplies, our research delves into the adoption of remanufacturing practices by medical product manufacturers as a strategic response to these shortages and environmental concerns. We investigate how government subsidies influence the production volumes of original manufacturers and remanufacturers and examine the competitive interplay between newly manufactured and remanufactured medical products. Through the development of three production game models-Scenario B (manufacturers produce both new and refurbished products), Scenario N (separate production of new and refurbished products by manufacturers and remanufacturers, respectively), and Scenario C (similar to Scenario N but includes a certification fee paid by remanufacturers to original manufacturers)-we analyze the strategies that could mitigate supply deficiencies during medical crises. Our findings indicate that the certification strategy (Scenario C) not only yields the highest total production of medical products but also offers a viable solution to enhance the sustainability of the entire medical production system by alleviating supply chain disruptions. Furthermore, we discuss the managerial implications of our results, emphasizing the potential of a joint remanufacturing strategy to stabilize the supply chain and foster environmental conservation. Lastly, we highlight our study's limitations and suggest future research directions, particularly concerning the variability in product quality and the reliance on government subsidies. This research contributes to a nuanced understanding of green remanufacturing within the pharmaceutical supply chain, offering insights for manufacturers, remanufacturers, and policymakers aiming for sustainable industry practices.
本研究探讨政府补贴对医疗产品供应链内生产动态的影响，特别关注医疗用品的再制造。在新冠疫情凸显医疗物资严重短缺的背景下，我们的研究深入探究医疗产品制造商采用再制造做法作为应对这些短缺和环境问题的战略举措。我们调查政府补贴如何影响原始制造商和再制造商的产量，并审视新生产和再制造医疗产品之间的竞争相互作用。通过开发三种生产博弈模型——情景B（制造商同时生产新产品和翻新产品）、情景N（制造商和再制造商分别单独生产新产品和翻新产品）以及情景C（类似于情景N，但包括再制造商向原始制造商支付的认证费用）——我们分析了在医疗危机期间可缓解供应不足的策略。我们的研究结果表明，认证策略（情景C）不仅能实现医疗产品的最高总产量，还能通过缓解供应链中断为增强整个医疗生产系统的可持续性提供可行方案。此外，我们讨论了研究结果的管理意义，强调联合再制造策略在稳定供应链和促进环境保护方面的潜力。最后，我们突出了本研究的局限性，并提出未来的研究方向，特别是关于产品质量的变异性和对政府补贴的依赖。这项研究有助于对药品供应链中的绿色再制造形成细致入微的理解，为旨在实现可持续行业实践的制造商、再制造商和政策制定者提供见解。
